PharmaBlock Sciences (Nanjing) Balance Sheet Health
Financial Health criteria checks 4/6
PharmaBlock Sciences (Nanjing) has a total shareholder equity of CN¥2.9B and total debt of CN¥1.5B, which brings its debt-to-equity ratio to 51.5%. Its total assets and total liabilities are CN¥4.9B and CN¥2.0B respectively. PharmaBlock Sciences (Nanjing)'s EBIT is CN¥211.9M making its interest coverage ratio 5.1. It has cash and short-term investments of CN¥596.5M.
Key information
51.5%
Debt to equity ratio
CN¥1.49b
Debt
| Interest coverage ratio | 5.1x |
| Cash | CN¥596.54m |
| Equity | CN¥2.90b |
| Total liabilities | CN¥2.02b |
| Total assets | CN¥4.92b |
Recent financial health updates
PharmaBlock Sciences (Nanjing) (SZSE:300725) Takes On Some Risk With Its Use Of Debt
Nov 22
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31Recent updates
PharmaBlock Sciences (Nanjing) (SZSE:300725) Takes On Some Risk With Its Use Of Debt
Nov 22PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce
Sep 30PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Aug 23We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Financial Position Analysis
Short Term Liabilities: 300725's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥806.3M).
Long Term Liabilities: 300725's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300725's net debt to equity ratio (30.9%) is considered satisfactory.
Reducing Debt: 300725's debt to equity ratio has increased from 12.3% to 51.5% over the past 5 years.
Debt Coverage: 300725's debt is not well covered by operating cash flow (19.2%).
Interest Coverage: 300725's interest payments on its debt are well covered by EBIT (5.1x coverage).